Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus

Lupus

Volumn 13, Issue 12, 2004, Pages 887-890

  Raptopoulou, Amalia ^a   Sidiropoulos, Prodromos ^a   Boumpas, Dimitrios T ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; AZATHIOPRINE; CALCIUM; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GONADORELIN AGONIST; LEUPRORELIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; RITUXIMAB; TESTOSTERONE; VITAMIN D;

AMENORRHEA; BONE DENSITY; EDITORIAL; FEMALE; FEMALE FERTILITY; HORMONE BLOOD LEVEL; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS GONAD SYSTEM; MENORRHAGIA; MENSTRUAL IRREGULARITY; OSTEOPOROSIS; OVARY INSUFFICIENCY; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFERTILITY, FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; OLIGOSPERMIA; OVARIAN FAILURE, PREMATURE;

EID: 10844228992     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu2029ed     Document Type: Editorial

References (40)

1. Pasoto SG, Viana VST, Mendonca BB. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol 1999; 26: 1087-1093.
2. Raz A, Fish B, Okon E. Possible direct cytoxicity effects of cyclophosphamide on cultures of human follicles: an electron microscopy study. J Assist Reprod Genet 2002; 19: 500-506.
3. Boumpas DT, Austin HA, Vaughan EM et al. Rise for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366-369.
4. Lim GS, Petri M, Goldman D. Menstruation and systemic lupus erythematosus: a case control study. Arthritis Rheum 1993; 36 (Suppl. 5): R23.
5. Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus 1995; 4: 11-14.
6. McDermott EM, Powell RI. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55: 224-229.
7. Pasoto SG, Mendonca BB, Bonfa E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 2002; 11: 175-180.
8. Moncayo R, Moncayo HE. Autoimmunity and the ovary. Immunol Today 1992; 13: 255-258.
9. Moncayo R, Moncayo H. Serum levels of CA 125 are elevated in patients with systemic lupus erythematosus. Obstet Gynecol 1991; 77: 932-934.
10. Jacobi AM, Rohde W, Ventz M et al. Enchanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity. Lupus 2000; 10: 554-561.
11. Jimena P, Aguirre MA, Lopez-Curbelo A. Prolactin levels in patients with systemic lupus erythematosus: a case controlled study. Lupus 1998; 7: 383-386.
12. Leanos A, Pascal D. Anti-prolactin autoantibodies in SLE patients with associated hyperprolactinemia. Lupus 1998; 7: 398-403.
13. Rovensky J, Jurankova E, Rauova L. Relationship between endocrine, immune and clinical variables in patients with systemic lupus erythematosus. J Rheumatol 1997; 24: 2330-2334.
14. Flanc RS, Roberts MA, Strippoli GF et al. Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004; 43: 197-208.
15. Gonzalez MR, Gomez JJ, Merino R. Mensrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995; 34: 737-741.
16. McDermott EM, Powell RJ. Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55: 224-229.
17. Ioannidis JP, Katsifis GE, Tzioufas AG, Moutsopoulos HM. Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopauseal women with systemic lupus erythematosus. J Rheumatol 2002; 29: 2129-2135.
18. Takada K, Arefayene M, Desta Z et al. Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis. Arthritis Rheum 2004; 50: 2202-2210.
19. Meirow D, Lewis H, Nugent D, Epstein M. Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod 1999; 14: 1903-1907.
20. Meirow D, Epstein M, Lewis H, Nugent D, Gosden RG. Administration of cyclophosphamide at different stages of follicular maturation in mice: effects on reproductive performance and fetal malformations. Hum Reprod 2001; 16: 632-637.
21. Letterie GS. Anovulation in the prevention of cytotoxic-induced follicular attrition and ovarian failure. Hum Reprod 2004; 19: 831-837.
22. Wallace WH, Shalet SM, Tetlow LJ. Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1993; 21: 333-339.
23. Park M-C, Park Y-B, Jung SY et al. Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004; 13: 569-574.
24. Huong DLT, Amoura Z, Duhaut P et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 2002; 29: 2571-2576.
25. Slater CA, Liang MH, McCune JW, Christman GM, Laufer MR. Preserving ovarian function in patients receiving cyclophosphamide. Lupus 1999; 8: 3-10.
26. Meirow D, Assad G, Dor J, Rabinovici J. The GnRH antagonist cetrorelix reduces cyclophosphamide-induced ovarian follicular destruction in mice. Hum Reprod 2004; 19: 1294-1299.
27. Dooley MA. Pattterson CC, Susan L et al. Preservation of ovarian function using depot leuprolide acetate during cyclophosphamide therapy for severe lupus nephritis. Arthritis Rheum 2000; 43: 2858.
28. Dooley MA, Falk RJ, Jennette JC et al. Variable bone mineral density changes in women receiving depot leuprolide acetate during cyclophosphamide therapy for severe lupus nephritis. Arthritis Rheum 1998; 40 (Suppl. 9): Abstract.
29. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated with chemotherapy. Lupus 2000; 9: 401-405.
30. Ghosh S, Monomohon M, Baran D et al. Effect of human chorionic gonadotrophin coadministration on ovarian steroidogenic and folloculogenic activities in cyclophosphamide treated albino rats. Reprod Toxicol 2001; 15: 221-225.
31. Pendse S, Ginsburg E, Singh AK. Strategies for preservation of ovarian and testicular function after immunosupression. Am J Kidney Dis 2004; 43:772-781.
32. Blumenfeld Z. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers. Mol Cell Endocrinol 2002; 187: 93-105.
33. Masala A, Faedda R, Alagna S et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997: 15; 126: 292-295.
34. Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update 2001; 7: 363-369.
35. Contreras G, Pardo V, Baudouin L et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350: 971-980.
36. Chan TM, Li FK, Colin SO et al. Efficacy of mycophenolate mofetil in patients with diffuseproliferative lupus nephritis. N Engl J Med 2000; 343: 1156-1162.
37. Balow JE, Austin HA. Maintenance therapy for lupus nephritis -something old, something new. N Engl J Med 2004; 350: 1044-1046.
38. Looney RJ, Anolik J, Sanz I. B lymphocytes in systemic lupus erythematosus: lessons from therapy targeting B cells. Lupus 2004; 13: 381-390.
39. Gorman C, Leandro M, Isenberg D. Does B cell depletion have a role to play in the treatment of systemic lupus erythematosus? Lupus 2004; 13: 312-316.
40. Weide R, Heymanns J, Randorf A, Koppler H. Successful long-term treatment of SLE with rituximab maintenance therapy. Lupus 2003; 12: 779-782.